力生制药发布2021年第三季度报告，实现营业收入2.48亿元，同比下降17.66%；归属于上市公司股东的净利润3646.42万元，同比增长61.33%；归属于上市公司股东的扣除非经常性损益的净利润3579.28万元，同比增长57.46%；基本每股收益0.20元。
力生制药2021中报显示，公司主营收入5.87亿元，同比下降4.32%；归母净利润6125.28万元，同比上升8.28%；扣非净利润5865.19万元，同比上升4.93%；其中2021年第二季度，公司单季度主营收入2.6亿元，同比下降7.63%；单季度归母净利润2519.83万元，同比上升12.92%；单季度扣非净利润2331.18万元，同比下降8.71%；负债率14.68%，投资收益778.81万元，财务费用-2608.77万元，毛利率58.27%。
该股最近90天内无机构评级。近3个月融资净流出1785.49万，融资余额减少；融券净流入0.0万，融券余额增加。证券之星估值分析工具显示，力生制药（002393）好公司评级为2星，好价格评级为2星，估值综合评级为2星。
公司董事长为徐道情。徐道情先生:1962年8月出生,中国国籍,无境外永久居留权,在职研究生学历,学士学位,正高级工程师。历任天津市中央药业有限公司研究所课题负责人、主任、副所长、销售部副部长、市场部部长、副总经理;天津中新药业新新制药厂厂长兼任天津中新药业集团股份有限公司副总经理;天津中新药业隆顺榕制药厂党委书记、副厂长、天津新丰制药有限公司总经理;天津中新药业集团副总经理、总工程师;天津力生制药股份有限公司董事、副总经理;天津达仁堂京万红药业有限公司党总支书记、董事、副董事长和总经理。现任天津力生制药股份有限公司党委书记、董事、董事长;天津田边制药有限公司董事、董事长。
本文由证券之星数据中心根据公开数据汇总整理，不构成投资意见或建议，如有文中存在问题，请联系我们。
Lisheng Pharmaceutical released a report for the third quarter of 2021, with operating income of 248 million yuan, down 17.66% from the same period last year. Net profit belonging to shareholders of listed companies was 36.4642 million yuan, up 61.33% from the same period last year. Net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 35.7928 million yuan, up 57.46% from the same period last year; and basic earnings per share was 0.20 yuan.
According to the 2021 report of Lisheng Pharmaceutical, the company's main income was 587 million yuan, down 4.32% from the same period last year; the net profit was 61.2528 million yuan, up 8.28% from the same period last year; and deducting 58.6519 million yuan from non-net profit, up 4.93% from the same period last year. Among them, in the second quarter of 2021, the company's main income in a single quarter was 260 million yuan, down 7.63% from the same period last year; and the net profit in a single quarter was 25.1983 million yuan, up 12.92% from the same period last year. The non-net profit in a single quarter was 23.3118 million yuan, down 8.71% from the same period last year; the debt ratio was 14.68%, the investment income was 7.7881 million yuan, the financial expenses were-26.0877 million yuan, and the gross profit margin was 58.27%.
The stock has no agency rating in the last 90 days. In the past three months, the net outflow of financing was 17.8549 million, and the financing balance decreased; the net inflow of securities was 0, and the balance of securities lending increased. According to the Securities Star valuation analysis tool, Lisheng Pharmaceutical (002393) has a 2-star rating, a good price rating of 2 stars, and a comprehensive valuation rating of 2 stars.
The chairman of the company is Xu Daoqing. Mr. Xu Daoqing: born in August 1962, Chinese nationality, no permanent residence abroad, on-the-job graduate degree, bachelor's degree, senior engineer. He has successively served as the project leader, director, deputy director, deputy sales minister, marketing minister and deputy general manager of the Research Institute of Tianjin Central Pharmaceutical Co., Ltd.; the factory director of Tianjin Zhongxin Pharmaceutical Co., Ltd. is also the deputy general manager of Tianjin Zhongxin Pharmaceutical Group Co., Ltd.; party committee secretary, deputy factory director of Tianjin Zhongxin Pharmaceutical Longshunrong Pharmaceutical Factory, general manager of Tianjin Xinfeng Pharmaceutical Co., Ltd. Deputy General Manager and Chief engineer of Tianjin Zhongxin Pharmaceutical Group; Director and Deputy General Manager of Tianjin Lisheng Pharmaceutical Co., Ltd.; Party General Branch Secretary, Director, Vice Chairman and General Manager of Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd. He is currently the party committee secretary, director and chairman of Tianjin Lisheng Pharmaceutical Co., Ltd., and the director and chairman of Tianjin Tianbian Pharmaceutical Co., Ltd.
This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.
